Postsurgical Pain Clinical Trial
Official title:
A Phase 2, Randomized, Double-blind, Placebo-Controlled Efficacy, Pharmacokinetics and Safety Study of CA-008 (Vocacapsaicin) in Subjects Undergoing Total Knee Arthroplasty
Verified date | December 2021 |
Source | Concentric Analgesics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a two-part, Phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 (vocacapsaicin) vs. placebo injected/instilled during an elective TKA.
Status | Completed |
Enrollment | 55 |
Est. completion date | May 31, 2019 |
Est. primary completion date | April 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Key Inclusion Criteria: 1. Plan to undergo an elective primary unilateral total knee arthroplasty (TKA or knee replacement), without collateral procedure or additional surgeries. 2. Be a reasonably healthy adult aged 18 - 80 years old, inclusive, with a BMI = 36 kg/m2 and American Society of Anesthesiology (ASA) physical Class 1, 2 or 3 at the time of randomization. 3. Males and females must abstain from intercourse, use acceptable birth control methods or be sterile or otherwise incapable of having children. 4. Be willing and able to sign the informed consent form (ICF) 5. Be willing and able to complete study procedures and pain scales and to communicate meaningfully in English. Be able and willing to return for outpatient follow up visits as required. Key Exclusion Criteria: 1. In the opinion of the Investigator, 1. have a concurrent painful condition, other than pain in the knee to be replaced, that may require pain treatment during the study period. 2. have active skin disease or other clinically significant abnormality at the anticipated site of surgery that could interfere with the planned surgery. 2. Have a known allergy to chili peppers, capsaicin or the components of CA-008, ropivacaine, ketorolac, acetaminophen, fentanyl, hydromorphone, morphine or oxycodone. 3. Have significant medical, neuropsychiatric or other condition. 4. The following are considered disallowed medications: 1. tolerant to opioids as defined 2. capsaicin-containing products or foods. 3. central nervous system active agent as an analgesic adjunct medication 4. antiarrhythmics except beta-blockers, digoxin, warfarin, lithium, or aminoglycosides or other antibiotics for an infection 5. parenteral or oral corticosteroids. 6. antianginal, antihypertensive agent or diabetic regimen at a dose that has not been stable for at least 30 days or which is not expected to remain stable while participating in the study. 5. Have positive results on the alcohol breath/saliva test indicative of alcohol abuse or urine drug screen indicative of illicit drug use at screening, and/or prior to surgery. |
Country | Name | City | State |
---|---|---|---|
United States | HD Research | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Concentric Analgesics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time-specific Mean Pain Intensity Scores (NRS) at Time 96 Hours for CA-008 vs. Placebo | Primary Efficacy Endpoint for the Pilot Stage. Time-specific mean pain intensity scores at Time 96 hours for CA-008 vs. placebo based on a 10-point numerical rating scale (NRS) from 0-10 where 0 is no pain and 10 is the worst pain imaginable). | At 96 hours | |
Primary | CA-008 Dose vs. Placebo Comparison: Area Under the Curve (AUC) 0 to 96 Hours | Primary Efficacy Endpoint for Stage 2. Area Under the Curve (AUC) of the NRS current pain intensity scores from Time 0 hours to 96 hours at rest (AUC0 to 96h) where 0 is no pain and 10 is the worst pain imaginable for CA-008 compared to placebo. •
During the inpatient stay, NRS at rest beginning with the PACU admission may be assessed once the subject is awake. The maximum is an NRS score of 10 x all 96 hours = 960 NRS units*hrs; the minimum is 0 x 96h = 0 NRS units*hrs |
From 0 hours to 96 hours | |
Secondary | Percentage of Subjects Who do Not Require Opioids | Key Secondary Efficacy Endpoints for Stage 2. For each CA-008 dose vs. placebo comparison, percentage of subjects who do not require opioids. | Time 0 hours to Time 96 hours: Opioid Free 0 hours to 96 hours | |
Secondary | Total Opioid Consumption (in Daily Oral Morphine Equivalents) | Key Secondary Efficacy Endpoints for Stage 2. Mean total postoperative opioid consumption (in daily oral morphine equivalents) for CA-008 compared to placebo | OC from Time 0 hours to Time 96 hours: OC 0 hours to 96 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04774328 -
Preliminary Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair
|
Phase 1/Phase 2 | |
Recruiting |
NCT05193227 -
Sustained Release Lidocaine for the Treatment of Postoperative Pain
|
Phase 2 | |
Completed |
NCT01562483 -
The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain
|
Phase 2 | |
Completed |
NCT02081703 -
Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery
|
Phase 2 | |
Recruiting |
NCT04647435 -
Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction
|
Phase 3 | |
Completed |
NCT01582477 -
TAP-patients With Robotic Assisted Lap Prostatectomy
|
Phase 4 | |
Suspended |
NCT04681027 -
Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children
|
Phase 3 | |
Completed |
NCT05607641 -
Efficacy and Safety Study of Ketorolac / Pitofenone / Fenpiverinium for the Treatment of Patients With Pain After Surgical Abdominal and Pelvic Operations
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06202989 -
Multiprofen-CC™ to Reduce Pain After Total Knee Arthroplasty
|
Phase 3 | |
Completed |
NCT01731730 -
Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery
|
Phase 2 | |
Recruiting |
NCT05698914 -
Telehealth Mindfulness After Spine Surgery
|
N/A | |
Completed |
NCT04203537 -
Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin)
|
Phase 1/Phase 2 | |
Completed |
NCT03789318 -
Study in Subjects Undergoing Complete Abdominoplasty
|
Phase 2 | |
Completed |
NCT04648683 -
Postoperative Telehealth Mindfulness Intervention After Spine Surgery
|
N/A | |
Completed |
NCT06412380 -
Influence of Insertion Torque and Bone Type on Post-operative Pain
|
N/A | |
Recruiting |
NCT05394402 -
A Trial of SHR0410 Injection in Postsurgical Pain Management
|
Phase 2 | |
Not yet recruiting |
NCT06344169 -
Dinalbuphine Ester (Naldebain) for Pain Management After Cesarean Section
|
Phase 2/Phase 3 |